Chris SloanDirector, Market Access Strategy at Blueprint Medicines
Chris is a Director of Market Access Strategy at Blueprint Medicines and has 10+ years’ experience in consulting and life sciences industries. He specializes in the intersections of US market access, drug pricing, and policy reforms. His economic analyses of key policy proposals and issues, including drug pricing and the repeal and replace efforts around the ACA, have been featured in a wide range of publications, including the Wall Street Journal, the New York Times, the Washington Post, and Politico. He holds an MS in Healthcare Decision Analysis from the University of Southern California and a BBA in Economics from the College of William & Mary.